References
- Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. Ca Cancer J Clin 2005;55:74–108
- Kohne CH, Schoffski P, Wilke H, et al. Effective biomodulation by leukovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418–26
- Poon MA, O’Connel MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407–18
- de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leukovorin and fluorouracil bolus with bimonthly high dose leukovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;14:808–15
- Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077–82
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leukovorin for metastatic colorectal cancer. New Engl J Med 2000;343:905–14
- Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000;355:1041–47
- Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053–71
- de Gramont A, Figer A, Seymour M, et al. Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47
- Goldberg R, Sargent Dj, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30
- Souglakos J, Mavroudis D, Kakolyris S, et al. A triplet combination with irinotecan (CPT-11) plus oxaliplatin (LOHP) plus continuous infusion 5-fluorouracil (5-FU) and leucovorin (LV) as first line treatment in metastatic colorectal cancer (MCC): a multicenter phase II trial. J Clin Oncol 2002;20: 2661–7
- Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;20:4006–14
- Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) versus FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) as first line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798–805
- Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford University Press; 1997
- Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford University Press; 1996
- Van Hout A, Maiwenn JA, Gordon GS, et al. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994;3: 309–19
- Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005;8:1–2
- Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670–6
- Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leukovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–14
- Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11:1–6